181 related articles for article (PubMed ID: 38860909)
1. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents.
Kang JX; Li C; Cheng YM; Huang MX; Zhao GK; Jin ZL; Qi XW; Gu J; Ouyang Q
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860909
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
3. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
[TBL] [Abstract][Full Text] [Related]
4. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.
Wang C; Zhang Y; Zhang T; Xu J; Yan S; Liang B; Xing D
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127440. PubMed ID: 37839594
[TBL] [Abstract][Full Text] [Related]
6. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
8. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract][Full Text] [Related]
11. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S; Zimmermann S; Adjei AA
Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy.
Peng Y; Tan J
Front Biosci (Landmark Ed); 2023 Aug; 28(8):163. PubMed ID: 37664928
[TBL] [Abstract][Full Text] [Related]
13. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
Schroeder RL; Stevens CL; Sridhar J
Molecules; 2014 Sep; 19(9):15196-212. PubMed ID: 25251190
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
Wang Y; Yin X; Chen L; Yin Z; Zuo Z
Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
[TBL] [Abstract][Full Text] [Related]
16. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-).
Hu L; Fan M; Shi S; Song X; Wang F; He H; Qi B
Eur J Med Chem; 2022 Jan; 227():113963. PubMed ID: 34749202
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
Shelton JG; Steelman LS; Abrams SL; Bertrand FE; Franklin RA; McMahon M; McCubrey JA
Expert Opin Ther Targets; 2005 Oct; 9(5):1009-30. PubMed ID: 16185155
[TBL] [Abstract][Full Text] [Related]
18. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
19. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
20. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
